ABSTRACT

Objective:

Hemifacial spasm (HFS) is a movement disorder of the seventh nerve which is characterised by involuntary clonic or tonic contractions of the muscles innervated by the facial nerve. In this study, we aimed to search whether there was a relationship between vitamin D status and severity of disease.

Methods:

Forty-six HFS patients were included to the study, who have been followed up in University of Health Sciences Antalya Training and Research Hospital, Neurology Department Movement Disorders outpatient clinic. Patients were regularly receiving botulinum toxin injections. Demographic features and vitamin D, calcium and phosphate levels were measured in winter. Severity of disease was rated on a 0-4 scale. The relationship between vitamin D status and the severity of disease was evaluated.

Results:

The mean age of the patients was 59.58±9.8 years. Thirty-five patients (76.1%) were female and 11 patients (23.9%) were male. Mean duration of disease was 5.30±4.59 years. Moderate and severe functional impairment were seen in most of the patients (n:18 (39.1%), moderate); n:15 (32.6%), severe, respectively). There was no significant difference between duration and severity of disease (p=0.512). Vitamin D levels were compared between four groups according to severity of disease scale and there was no significant difference (p=0.291).

Conclusion:

Even though there was no relationship between the severity of HFS and vitamin D status, further controlled studies in a larger population were needed to enlighten this finding.

Keywords: Hemifacial spasm, vitamin D, botulinum toxin

References

Chaudhry N, Srivastava A, Joshi L. Hemifacial spasm: The past, present and future. J Neurol Sci 2015 15;356:27-31.

Abbruzzese G, Berardelli A, Defazio G. Hemifacial spasm. Handb Clin Neurol 2011;100:675-80.

Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol 2010;121:297-300.

Kulie T, Groff A, Redmer J, Hounshell J, Schrager S, et al. Vitamin D: An evidence- based review. J Am Board Fam Med 2009;22:698-706.

Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev 2008; 66:116-24.

Calvello R, Cianciulli A, Nicolardi G, De Nuccio F, Giannotti L, Salvatore R, et al. Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson’s Disease, Shifting M1 to M2 Microglia Responses. J Neuroimmune Pharmacol 2017;12:327-39.

Tan EK, Fook-Chong S, Lum SY, Thumboo J. Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. J Neurol Neurosurg Psychiatry 2005;76:1707-10.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.

Li HH, Shan L, Wang B, Du L, Xu ZD, Jia FY. Serum 25-hyroxyvitamin D levels and tic severity in Chinese children with tic disorders. Psychiatry Res 2018;267:80-4.

Luo X, Ou R, Dutta R, Tian Y, Xiong H, Shang H. Association Between Serum Vitamin D Levels and Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Neurol 2018;9:909.

Vinh Quoc Luong K, Thi Hoang Nguyen L. Vitamin D and Parkinson’s disease. J Neurosci Res 2012;90:2227-36.

Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.

Peterson AL. A review of vitamin D and Parkinson’s disease. Maturitas 2014;78:40-4.

Tanaka K, Miyake Y, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y, et al. Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinson’s disease in Japan. Neurosci Lett 2017; 643:97-102.

Gatto NM, Sinsheimer JS, Cockburn M, Escobedo LA, Bordelon Y, Ritz B. Vitamin D receptor gene polymorphisms and Parkinson’s disease in a population with high ultraviolet radiation exposure. J Neurol Sci 2015;352:88-93.

Airavaara M, Voutilainen MH, Wang Y, Hoffer B. Neurorestoration. Parkinsonism Relat Disord. 2012;18:S143-6.

Rcom-H’cheo-Gauthier AN, Meedeniya AC, Pountney DL. Calcipotriol inhibits alpha-synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism. J Neurochem 2017;141:263-74.

Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitaminD metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-4.

Thouvenota E, Orsini M, Daures JP, Camu W. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing–remitting multiple sclerosis. Eur J Neurol 2015;22:564-9.

Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, De Luca HF et al. 1,25-Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells, Brain Res Mol Brain Res 1994;24:70-6.

Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-5.

Liu MX, Zhong J, Xia L, Dou NN, Li ST. A correlative analysis between inflammatory cytokines and trigeminal neuralgia or hemifacial spasm. Neurol Res 2019;41:335-40.

Pandey S, Jain S. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm. Neurol India 2018;66:1036-42.

Sezgin G, Ozturk G, Turkal R, Caykara B. Vitamin D Levels of Outpatients Admitted to a University Hospital in the Marmara Region of Turkey Over 3 Years. J Med Biochem 2019;38:181-7.

The Effect of Vitamin D on Severity of Hemifacial Spasm

ABSTRACT

References